Valproate Lawsuit Side Effects


              Valproate sodium is sodium salt of valproic acid designated as sodium 2-propylpentanoate and has a molecular weight of 166.2. It is a white and odorless, crystalline, deliquescent powder. Valproate sodium is an ingredient used in a drug called Depacon. The Depacon solution is available in 5mL single-dose vials for intravenous injection and each mL contains valporate sodium equal to 100mg valporic acid and .40mg of edentate disodium.

              Valproate sodium is in Depacon to assist monotherapy and adjunctive therapy in treatment of patients with complex partiel sezures that take place alone or in association with other types of seizures.

              Depacon has not yet been studied for intravenous use for periods of more than 14 days. Oral Valproate products should be assigned as soon as it is feasible clinically. Depacon should be given as a 60 minute infusion, not more than 20mg/min, with the same rate of recurrence as the oral products. Plasma concentration monitoring and dosage adjustment may be necessary however.

              For monotherapy, therapy should be initiated at 10 to 15mg/kg/day and to achieve optimal clinical response should be increased by 5 to 10mg/kg/week.

              For Conversion to Monotherapy, therapy should be initiated at 10 to 15mg/kg/day and should be increased by 5 to 10mg/kg/week.

              For Adjunctive Therapy, Depacon should be added to the patient’s regimen at a dosage of 10 to 15mg/kg/day and the dosage should be increased by 5 to 10mg/kg/week.

              Simple and Complex Absence Seizures the initial recommended dose is 15mg/kg/day and it should be increased by 5 to 10mg/kg/day until seizures or side effects preclude increase further.

              Depacon should be administered intravenously as a 60 minute infusion intravenously and should be diluted with at least 50mL of compatible duluent. The unused portion of Depacon should be discarded.

              The results of an interim study conducted by scientist at the University of Liverpool concluded that children exposed to valproate in-utero may have demonstrate lower IQs as toddlers than children whose mother took different epilepsy drugs.

              Some side affects and adverse reactions associated with Depacon include:

Chest Pain
Headache
Injection Site Inflammation
Injection Site Pain
Injection Site Reaction
Pain (unspecified
 Vasodilation
Sweating
Abdominal Pain
Diarrhea
Nausea
Vomiting
Dizziness
Euphoria
Hypesthesia
Nervousness
Paresthesia
Somnolence
Tremor
Pharyngitis
Taste Perversion
 

 

Discuss this article in the forums (0 replies).